Sebastian Gensior’s Post

Early stage returns by Bruce Booth at https://lnkd.in/e_kPu95F. A better prescription for drug-development financing by Mark Kessel and Frederick Frank at https://lnkd.in/ebaXzeMC. Highlights-Article 1 The initial public offerings (IPOs) process itself may be broken: a case of bankers shopping a development-stage company to a small set of well-connected biotech IPO investors who beat up the company on price, valuation and the amount of capital raised Veterans of big biotech success stories, such as Genentech, Amgen and Biogen-Idec, have been ‘seeding’ most of the major biotech clusters with talented émigrés eager to discover/rediscover more entrepreneurial roles Because each venture capital-VC firm partner can only invest and manage four to six new companies in a given fund (a relatively fixed number due to partner bandwidth and time), partners in larger funds need to put more capital in each deal and therefore cannot realistically focus on early-stage life science projects and technologies. Virtual biotechs are now a realistic alternative to classic biotech company-building. This breed of biotech is almost exclusively project-focused, has minimal infrastructure and relies solely on external service providers for execution. These three attributes make for both simpler governance and lower cash burn rates

Private equity and venture capital success stories in healthcare 🏆   On Rare Disease Day, find out how the asset class supports healthcare and biotech businesses across Europe, supporting their development of novel treatments.   Filter by sector, country or type of investor ⤵️   ➡️ https://lnkd.in/ec3A-mrA   #InvestEurope #PrivateEquity #VentureCapital #BuildingBetterBusinesses #SuccessStories #RareDiseaseDay

Many thanks to STAT for hosting “STAT in NYC: A Look Ahead at Biotech in 2024” held last night. We find ourselves still thinking about the conversations, especially the one between STAT’s Adam Feuerstein and Avoro Capital Advisors (formerly venBio Select Advisor) managing partner Behzad Aghazadeh. Here are some perspectives of note shared during the discussion on the current biotech landscape in case you missed:  - During 2020-2021, far too many biotech companies were formed and funded, with ~$50 billion raised via IPO’s and follow-ons. Unfortunately, about 70% of that capital has disappeared. Of course, some of that value could come back – but that is the current situation. - Development-stage biotech capital markets are significantly undervalued when compared to other indexes. Once you remove big biotech from the equation, the cumulative market cap of public biotech companies is only ~$360 billion. A very small move of cash back into biotechs from funds in tech (even just 5%) would result in a rapid and dramatic value increase across our sector. - And what would trigger these funds to move back into development-stage biotech? According to Dr. Aghazadeh, interest rates need to stabilize at lower levels AND the industry needs to deliver. It’s been a tough year or two on the clinical front – investors need to see some successes, particularly in programs where there is a clear and not too complicated commercial market readthrough.      We’re looking forward to STAT’s next event.  

Promising growth in life sciences investment in 2020-22, found by British Business Bank's #EquityTracker23 report. With digital health experiencing the fastest growth of 157%, compared to 2017-19. The UK invested more in life sciences than Germany, France and Canada combined in 2020-22, more than £10.5bn venture capital raised by our life sciences companies. You can read the full report for more insights via link in the comments 👇 #LifeSciences #VentureCapital

🚀 Thriving Against the Odds! European-focused VC firms, Forbion and BioGeneration Ventures, break records in biopharma fund raises despite a slower 2023 market. Investors, from Eli Lilly to pension funds, express confidence in the societal impact of life sciences. 💰 Robust Funding Rounds Amid IPO Chill Large funding rounds keep European biotechs well-funded despite a cool IPO scene. 🔬 Sector Resilience and Top-Tier Investments Top-tier companies continue to attract significant capital, showcasing the sector's resilience. Novo Holdings backs the strength of the sector, highlighting significant funds still in play. 🌍 Value Proposition: European Biopharmas European biopharmas remain a compelling value proposition—40-50% cheaper than their U.S. counterparts. #BiotechInvesting #EuropeanBiotech #VCfunding #InnovationThrives Link to the article on the comment section below:

Attending the Women’s Health Innovation Summit 2023 in Boston? Join us for a panel discussion with Megann Watters, head of the Labcorp Venture Fund, on how new #biomarkers, solutions and alternative sample types are disrupting the #diagnostic landscape. Learn more about the Labcorp Venture Fund. #WomensHealth #WHIS23

Biotech startups face challenges in raising capital for clinical trials and product commercialization. Finance in a Box offers fundraising assistance and investor relations support to attract funding and propel Biotech innovations to market success. Let's secure the funding you need for groundbreaking healthcare solutions! #BiotechFunding #FinanceInABox #CFOservices #GAoutsourcing #FinanceSolutions #BusinessConsulting #FinancialManagement #OutsourcedFinance #CFOadvisory #GrowthAdvisory #BusinessStrategy #FinancialPlanning #CostOptimization #RevenueGrowth #OperationalExcellence #AccountingServices #BusinessPerformance #EfficiencyImprovement #Profitability #RiskManagement #StrategicAdvisory #FinanceTransformation

🌐 Insights from Jefferies London Healthcare Conference! 🏥 Antoine Papiernik, Chairman of Sofinnova Partners, shares thoughts on the biotech landscape and funding trends. 💡 🌍 Despite a challenging year, optimism is in the air among attendees. Papiernik notes the positivity and highlights the 740 million euro fund by Gilde Healthcare as evidence that "there's money around." 💰 📉 Funding Challenges: Acknowledging the difficulty in securing funds, Papiernik emphasizes the importance of catching available opportunities, indicating a more positive sentiment than expected. 🚀 🔍 IPO Landscape: Papiernik remains cautious about a significant shift in the IPO landscape, suggesting that acquisitions might be the primary exit route for biotechs. 🔄 🤝 Pharma Appetite: The silver lining lies in the strong appetite among Big Pharmas for biotech acquisitions, demonstrated by recent moves like Eli Lilly and Company acquiring Sofinnova's portfolio company, Mablink Bioscience. 🌐 💼 Future Predictions: Papiernik anticipates potential changes in M&A activity, leading to more transactions and addressing pent-up demand in the biotech sector. 📈 👏 Kudos to the organisers of Jefferies London Healthcare Conference for fostering collaboration and discussions in the European biotech landscape! 🇪🇺💊 #Biotech #HealthcareConference #FundingTrends #IPO #BiotechInvestment #MandA #SofinnovaPartners #JefferiesConference #InnovationInHealthcare 🚑🔬

Pictet Group has announced the close of its first healthcare-focused thematic private equity fund at $320m – exceeding its target size of $300m. It invests in five segments: therapeutics, diagnostics, digital health, medical technology, and healthcare providers and service providers. The fund was launched in 2022 and is managed by Yann Mauron, Ph.D, David Braga Malta and Chiara Brambillasca. Pictet has now raised a total of $950m across its thematic private equity franchise, from a mixture of high-net-worth and institutional investors. In 2022, Yann Mauron, said: "Health is a high priority for society as a whole. We are at a tipping point for breakthroughs in medicine: investment is increasing, regulation is providing more support, and technology offers more potential solutions." #PEInsights #privateequity #investment #healthcareindustry

Biotech research and development serve as the bedrock of groundbreaking advancements, but the journey often demands substantial financial backing. CEOs spearheading these ventures find themselves seeking strategic funding avenues to nurture their companies’ growth and innovation. Licensing emerges as a powerful and versatile approach, presenting an array of opportunities to secure the capital necessary for expansion. Here’s a closer look at six key licensing avenues at the disposal of a Biotech CEO. https://lnkd.in/dnQKwEP6 #BiotechInnovation #LicensingStrategies #InnovationLandscape #BiotechGrowth #CollaborationMatters